Article Data

  • Views 391
  • Dowloads 151

Original Research

Open Access

Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer

  • Y. S. Lee1
  • J. M. Baek2
  • E. K. Park1
  • C. J. Kim1
  • H. J. Lee3
  • J. O. Kim4,*,

1Department of Obstetrics and Gynecology, Daejeon (Republic of Korea)

2Department of General Surgery, College of Medicine, The Catholic University of Korea, Seocho-gu, Seoul

3Department of Pathology, Bucheon St. Mary’s Hospital, College of Medicine,The Catholic University of Korea, Wonmi-gu, Bucheon, Gyeonggi-do

4Department of Pathology, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea,Jung-gu, Daejeon (Republic of Korea)

DOI: 10.31083/j.ejgo.2020.01.4887 Vol.41,Issue 1,February 2020 pp.65-69

Published: 15 February 2020

*Corresponding Author(s): J. O. Kim E-mail:


Purpose of Investigation: To evaluate macrophage migration inhibitory factor (MIF) and CD74 expression in ovarian cancer, and to explore whether these expression levels correlate with clinicopathologic parameters. Materials and Methods: A total of 151 tissue samples were collected from May 2009 through May 2015. The collected samples included ten normal ovaries, 41 benign epithelial ovarian tumors, 38 borderline tumors, and 62 malignant epithelial ovarian tumors. CD74 and MIF expression was assessed by immunohistochemistry and a retrospective study was conducted. Results: Immunohistochemical analysis showed that MIF and CD74 expression was significantly higher in ovarian tumors, including ovarian cancer, than in normal ovary tissues. Furthermore, high MIF expression was correlated with lymph node metastasis (p = 0.048) and ovary surface invasion (p = 0.039). Conclusion: The present findings suggest that co-expression of MIF and CD74 in ovarian cancer is associated with poor clinical parameters and may serve as a therapeutic target for the treatment of ovarian cancer


Ovarian tumor; CD74; Macrophage migration inhibitory factor (MIF); Immunohistochemistry

Cite and Share

Y. S. Lee,J. M. Baek,E. K. Park,C. J. Kim,H. J. Lee,J. O. Kim. Expression and therapeutic potential of macrophage migration inhibitory factor and CD74 in ovarian cancer. European Journal of Gynaecological Oncology. 2020. 41(1);65-69.


[1] Grieb G., Kim B.S., Simons D., Bernhagen J., Pallua N.: “MIF and CD74 - suitability as clinical biomarkers”. Mini Rev. Med. Chem., 2014, 14, 1125.

[2] Agarwal R., Whang D.H., Alvero A.B., Visintin I., Lai Y., Segal E.A. et al.: “Macrophage migration inhibitory factor expression in ovarian cancer”. Am. J. Obstet. Gynecol., 2007, 196, 348 e1.

[3] Richard V., Kindt N., Saussez S.: “Macrophage migration inhibitory factor involvement in breast cancer (Review)”. Int. J. Oncol., 2015, 47, 1627.

[4] Hudson J.D., Shoaibi M.A., Maestro R., Carnero A., Hannon G.J., Beach D.H.: “A proinflammatory cytokine inhibits p53 tumor suppressor activity”. J. Exp. Med., 1999, 190, 1375.

[5] Tan X., Wu Q., Cai Y., Zhao X., Wang S., Gao Z. et al.: “Novel association between CD74 polymorphisms and hematologic toxicity in patients with NSCLC after platinum-based chemotherapy”. Clin. Lung Cancer, 2014, 15, 67.

[6] Krockenberger M., Engel J.B., Kolb J., Dombrowsky Y., Hausler S.F., Kohrenhagen N. et al.: “Macrophage migration inhibitory factor expression in cervical cancer”. J. Cancer Res. Clin. Oncol., 2010, 136, 651.

[7] Zheng Y.X., Yang M., Rong T.T., Yuan X.L., Ma Y.H., Wang Z.H. et al.: “CD74 and macrophage migration inhibitory factor as therapeutic targets in gastric cancer”. World J. Gastroenterol., 2012, 18, 2253.

[8] Richard V., Kindt N., Decaestecker C., Gabius H.J., Laurent G., Noel J.C. et al.: “Involvement of macrophage migration inhibitory factor and its receptor (CD74) in human breast cancer”. Oncol. Rep., 2014, 32, 523.

[9] Otterstrom C., Soltermann A., Opitz I., Felley-Bosco E., Weder W., Stahel R.A. et al.: “CD74: a new prognostic factor for patients with malignant pleural mesothelioma”. Br. J. Cancer, 2014, 110, 2040.

[10] Cheng R.J., Deng W.G., Niu C.B., Li Y.Y., Fu Y.: “Expression of macrophage migration inhibitory factor and CD74 in cervical squamous cell carcinoma”. Int. J. Gynecol. Cancer, 2011, 21, 1004.

[11] Schinagl A., Thiele M., Douillard P., Volkel D., Kenner L., Kazemi Z. et al.: “Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer”. Oncotarget, 2016, 7, 73486.

[12] Cheng S.P., Liu C.L., Chen M.J., Chien M.N., Leung C.H., Lin C.H. et al.: “CD74 expression and its therapeutic potential in thyroid carcinoma”. Endocr. Relat. Cancer, 2015, 22, 179

[13] Meza-Romero R., Benedek G., Jordan K., Leng L., Pantouris G., Lolis E. et al.: “Modeling of both shared and distinct interactions between MIF and its homologue D-DT with their common receptor CD74”. Cytokine, 2016, 88, 62.

[14] Lue H., Thiele M., Franz J., Dahl E., Speckgens S., Leng L. et al.: “Macrophage migration inhibitory factor (MIF) promotes cell survival by activation of the Akt pathway and role for CSN5/JAB1 in the control of autocrine MIF activity”. Oncogene, 2007, 26, 5046.

[15] Ishigami S., Natsugoe S., Tokuda K., Nakajo A., Iwashige H., Aridome K. et al.: “Invariant chain expression in gastric cancer”. Cancer Lett., 2001, 168, 87.

[16] Pei X.J., Wu T.T., Li B., Tian X.Y., Li Z., Yang Q.X.: “Increased expression of macrophage migration inhibitory factor and DJ-1 contribute to cell invasion and metastasis of nasopharyngeal carcinoma”. Int. J. Med. Sci., 2014, 11, 106.

[17] Hansen H.J., Ong G.L., Diril H., Valdez A., Roche P.A., Griffiths G.L. et al.: “Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas”. Biochem. J., 1996, 320, 293.

[18] Berkova Z., Tao R.H., Samaniego F.: “Milatuzumab - a promising new immunotherapeutic agent”. Expert Opin. Investig. Drugs, 2010, 19, 141.

[19] Christian B.A., Poi M., Jones J.A., Porcu P., Maddocks K., Flynn J.M. et al.: “The combination of milatuzumab, a humanized antiCD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma”. Br. J. Haematol., 2015, 169, 701.

[20] Haran M., Mirkin V., Braester A., Harpaz N., Shevetz O., Shtreiter M. et al.: “A phase I-II clinical trial of the anti-CD74 monoclonal antibody milatuzumab in frail patients with refractory chronic lymphocytic leukaemia: A patient based approach”. Br. J. Haematol., 2018, 182, 125.

[21] Rangel L.B., Agarwal R., Sherman-Baust C.A., Mello-Coelho V., Pizer E.S., Ji H. et al.: “Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers”. Cancer Biol. Ther., 2004, 3, 1021.

[22] Krockenberger M., Kranke P., Hausler S., Engel J.B., Horn E., Nurnberger K. et al.: “Macrophage migration-inhibitory factor levels in serum of patients with ovarian cancer correlates with poor prognosis”. Anticancer Res., 2012, 32, 5233.

[23] Hagemann T., Robinson S.C., Thompson R.G., Charles K., Kulbe H., Balkwill F.R.: “Ovarian cancer cell-derived migration inhibitory factor enhances tumor growth, progression, and angiogenesis”. Mol. Cancer Ther., 2007, 6, 1993.

[24] Lechien J.R., Kindt N., Costa Pde A., Chantrain G., Preillon J., Laurent G. et al.: “MIF in head and neck cancer: a new therapeutic target ?”. Rev. Laryngol. Otol. Rhinol. (Bord.), 2013, 134, 67.

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time